1596. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 104 Results

BACKGROUND: Lenacapavir (LEN) is a highly potent, long-acting, first-in-class inhibitor of HIV-1 capsid protein for the treatment of HIV-1 infection in adults with multidrug resistance (MDR) in combination with other antiretrovirals. METHODS: CAPELLA is an ongoing, phase 2/3 study in heavily treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogbuagu, Onyema, DeJesus, Edwin, Berhe, Mezgebe, Richmond, Gary J, Ruane, Peter J, Sinclair, Gary I, Ramgopal, Moti N, Sanchez, William, Crofoot, Gordon E, Margot, Nicolas A, Wang, Hui, Dvory-Sobol, Hadas, Rhee, Martin, Baeten, Jared, Segal-Maurer, Sorana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677747/
http://dx.doi.org/10.1093/ofid/ofad500.1431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677747/
http://dx.doi.org/10.1093/ofid/ofad500.1431

Ejemplares similares